Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a favourable immunological response.Read more »
Below you can find the latest news releases from Desentum.
Desentum Oy:n varsinainen yhtiökokous pidetään 25.5.2021 / The AGM of Desentum Oy is to be held on May 25th, 2021.Read more »
Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel allergy vaccine intended for treating birch pollen allergy. Last follow-up visits will be completed during Q2/2021 and study results are expected in Q3/2021.Read more »
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt.Read more »
Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site.Read more »